InVivoPlus anti-mouse NK1.1

Burrack KS, Huggins MA, Taras E, et al. Interleukin-15 Complex Treatment Protects Mice from Cerebral Malaria by Inducing Interleukin-10-Producing Natural Killer Cells. Immunity. 2018,48(4):760-772.e4. doi: 10.1016/j.immuni.2018.03.012

Glasner A, Levi A, Enk J, et al. NKp46 Receptor-Mediated Interferon-γ Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis. Immunity. 2018,48(1):107-119.e4. doi: 10.1016/j.immuni.2017.12.007

Moynihan KD, Opel CF, Szeto GL, et al. Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. Nat Med. 2016,22(12):1402-1410. doi: 10.1038/nm.4200

Ghasemi R, Lazear E, Wang X, et al. Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy. Nat Commun. 2016,7:12878. doi: 10.1038/ncomms12878

Ludigs K, Jandus C, Utzschneider DT, et al. NLRC5 shields T lymphocytes from NK-cell-mediated elimination under inflammatory conditions. Nat Commun. 2016,7:10554. doi: 10.1038/ncomms10554

Maltez VI, Tubbs AL, Cook KD, et al. Inflammasomes Coordinate Pyroptosis and Natural Killer Cell Cytotoxicity to Clear Infection by a Ubiquitous Environmental Bacterium. Immunity. 2015,43(5):987-97. doi: 10.1016/j.immuni.2015.10.010

Mitchell DA, Batich KA, Gunn MD, et al. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature. 2015,519(7543):366-9. doi: 10.1038/nature14320

Wensveen FM, Jelenčić V, Valentić S, et al. NK cells link obesity-induced adipose stress to inflammation and insulin resistance. Nat Immunol. 2015,16(4):376-85. doi: 10.1038/ni.3120

Yamada DH, Elsaesser H, Lux A, et al. Suppression of Fcγ-receptor-mediated antibody effector function during persistent viral infection. Immunity. 2015,42(2):379-390. doi: 10.1016/j.immuni.2015.01.005

Walsh KB, Teijaro JR, Brock LG, et al. Animal model of respiratory syncytial virus: CD8+ T cells cause a cytokine storm that is chemically tractable by sphingosine-1-phosphate 1 receptor agonist therapy. J Virol. 2014,88(11):6281-93. doi: 10.1128/JVI.00464-14